Traders News Source Issues Stocks on Watch and a New Feature Report
January 25 2018 - 8:05AM
InvestorsHub NewsWire
January 25, 2018 -- InvestorsHub
NewsWire -- Traders News Source, a leading independent equity
research and corporate access firm focused on small and mid-cap
public companies is issuing a comprehensive report with no
obligation on Atossa Genetics Inc (NASDAQ:
ATOS), BioPharmX Corporation (NYSE:
BPMX), Avinger, Inc. (NASDAQ:
AVGR) and Cytori Therapeutics, Inc. (NASDAQ:
CYTX) and a feature report in one of the hottest sectors in the
market.
Atossa Genetics Inc. (NASDAQ:ATOS) First quarter of 2018 Atossa
Genetics Inc. will commence the Phase 2 Study of topical Endoxifen
to treat mammographic breast density (or MBD) at Stockholm South
General Hospital in Sweden. Defined Health, a leading market
research firm, estimates that the potential market for Endoxifen
exceeds $1 billion in annual sales. Atossa is a clinical-stage
pharmaceutical company developing therapeutic and delivery methods
to treat breast cancer.
Get our latest research on a highly-undervalued oil and gas company
READ MORE
Copy and paste to your browser may be required to view the
report – http://bit.ly/2BoBy1P-Feature-Report
BioPharmX Corporation (NYSE: BPMX) Acne patients may soon have
another option, which some doctors call the “holy grail” of acne
care: a truly safe and effective topical therapy expecting to
launch phase three clinical trials for BPX-01 soon. Their focus is
to develop products that treat health or age-related conditions
that are not presently being addressed, treated or are treated with
less than the highest standard drug therapies.
Avinger, Inc. (NASDAQ: AVGR) Avinger announced that Arne Schwindt,
M.D., a vascular surgeon at St. Franziskus Hospital in Münster,
Germany, has successfully treated the first seven patients with a
is a minimally invasive treatment designed by the next generation
Avinger, Inc. atherectomy system. Avinger is a commercial-stage
medical device company that designs, manufactures and sells
image-guided, catheter-based systems that are used by physicians to
treat patients with peripheral arterial disease.
Get our latest research on a highly-undervalued oil and gas company
READ MORE
Copy and paste to your browser may be required to view the
report – http://bit.ly/2BoBy1P-Feature-Report
Cytori Therapeutics, Inc. (NASDAQ: CYTX) recently Cytori just
announced completion of patient enrollment in SCLERADEC II
(NCT02558543), a randomized, double-blind, placebo-controlled,
parallel group, multi-center clinical trial intended to study the
safety and efficacy of Habeo™ Cell Therapy in up to 40 subjects.
They develop cell therapies that harness the unique traits of
current living cells in adult patients to promote healing by using
the company's own patented Celution System. Celution System is
designed to repair injured tissue, preserve function, improve
quality of life, and modify disease progression.
FORWARD-LOOKING
DISCLAIMER
This press release may contain
certain forward-looking statements and information, as defined
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, and is subject
to the Safe Harbor created by those sections. This material
contains statements about expected future events and/or financial
results that are forward-looking in nature and subject to risks and
uncertainties. Such forward-looking statements involve risks,
uncertainties and other factors, which may cause the actual
results, performance or achievements of the subject company in this
report to be materially different from the statements made
herein.
COMPLIANCE PROCEDURE
Content is researched, written and
reviewed on a best-effort basis. Information in this release is
fact checked and produced on a best efforts basis. However, we are
only human and are prone to make mistakes. If you notice any errors
or omissions, please notify us below. The subject Company has not
compensated Traders News Source for the creation or dissemination
of this report. Traders News Source is the party responsible for
issuing the press release and for hosting the full analyst report
on Traders News Source website.
NOT FINANCIAL ADVICE
Traders News Source makes no
warranty, expressed or implied, as to the accuracy or completeness
or fitness for a purpose (investment or otherwise), of the
information provided in this document. This information is not to
be construed as personal financial advice. Readers are encouraged
to consult their personal financial advisor before making any
decisions to buy, sell or hold any securities mentioned
herein.
NO WARRANTY OR LIABILITY
ASSUMED
Traders News Source is not
responsible for any error which may be occasioned at the time of
printing of this document or any error, mistake or shortcoming. No
liability is accepted by Traders News Source whatsoever for any
direct, indirect or consequential loss arising from the use of this
document. Traders News Source expressly disclaims any fiduciary
responsibility or liability for any consequences, financial or
otherwise arising from any reliance placed on the information in
this document. Traders News Source does not (1) guarantee the
accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
Source: Traders News
Source
Contact:
editor@tradersnewssource.com
BioPharmX (AMEX:BPMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioPharmX (AMEX:BPMX)
Historical Stock Chart
From Sep 2023 to Sep 2024